News & Updates
Showing Hepatology articles
Showing

HCC risk higher in MASLD patients who smoke, drink alcohol
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at greater risk of developing incident hepatocellular carcinoma (HCC) when factors such as smoking, alcohol use, obesity, diabetes, and hypertension are present, according to a study. However, use of statin, metformin, or aspirin may modify disease progression.

FASN inhibitor for MASH with fibrosis gets a pass to phase III
The oral fatty acid synthase (FASN) inhibitor denifanstat appears to produce meaningful improvements in metabolic dysfunction-associated steatohepatitis (MASH) and stage 2–3 fibrosis, as shown in the results of a phase IIb trial.

Survodutide safe to use in cirrhosis patients
Treatment with survodutide, which has previously shown its efficacy in reducing body weight and glycaemia in people with obesity or type 2 diabetes, is well tolerated by patients with compensated or decompensated cirrhosis, reports a study.

New model predicts HCC risk in noncirrhotic CHB patients
A novel prognostic model based on the viral loads of hepatitis B virus (HBV) demonstrates its utility in predicting and stratifying the risk of hepatocellular carcinoma (HCC) in noncirrhotic patients with chronic hepatitis B (CHB) who are not yet receiving antiviral therapy.




